Maxim Group Maintains Buy On Inovio Pharmaceuticals Following DARPA Grant
In a research report issued Wednesday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target of $18, as the company received DARPA grant for infectious disease collaborative study.
Kolbert noted, “We see this collaborative grant as good news that supports our optimism on the Inovio technology. This collaboration brings Inovio’s DNA-based monoclonal antibody technology together with MedImmune’s expertise in infectious disease vaccine development, and a novel technology from the University of Pennsylvania to develop rapid protection against emerging infections.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 5.0% and a 43.2% success rate. Kolbert has a 8.7% average return when recommending INO, and is ranked #684 out of 3337 analysts.